The effect of IL17 and IL23 inhibitors on hematological parameters and C-reactive protein in psoriasis patients

References

• Cemil BC, Ataş H. The effect of biological treatment on to systemic inflammatory markers and plateletcrit in psoriasis patients. Dicle Med J. 2016;43:477–831.
   Google Scholar
• Gulliver WP, Young HM, Bachelez H, et al. Psoriasis patients treated with biologics and methotrexate have a reduced rate of myocardial infarction: a collaborative analysis using international cohorts. J Cutan Med Surg. 2016;20(6):550–554. doi: 10.1177/1203475416658004.
   PubMed Web of Science ®Google Scholar
• Paul C, Gourraud PA, Bronsard V, et al. Evidence-based recommendations to assess psoriasis severity: systematic literature review and expert opinion of a panel of dermatologists. J Eur Acad Dermatol Venereol. 2010;24(Suppl 2):2–9. doi: 10.1111/j.1468-3083.2009.03561.x.
   PubMedGoogle Scholar
• Polat M, Bugdayci G, Kaya H, et al. Evaluation of neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio in turkish patients with chronic plaque psoriasis. Acta Dermatovenerol Alp Pannonica Adriat. 2017;26(4):97–100.
   PubMedGoogle Scholar
• Ataseven A, Bilgin AU, Kurtipek GS. The importance of neutrophil lymphocyte ratio in patients with psoriasis. Mater Sociomed. 2014;26(4):231–233. doi: 10.5455/msm.2014.231-233.
   PubMedGoogle Scholar
• Ünal M, Küçük A, Ürün Ünal G, et al. Mean platelet volume, neutrophil to lyphocyte ratio and platelet to lymphocyte ratio in psoriasis. TURKDERM. 2015;49(2):112–116. doi: 10.4274/turkderm.57984.
   Google Scholar
• Yurtdaş M, Yaylali YT, Kaya Y, et al. Neutrophil-to-lymphocyte ratio may predict subclinical atherosclerosis in patients with psoriasis. Echocardiography. 2014;31(9):1095–1104. doi: 10.1111/echo.12511.
   PubMed Web of Science ®Google Scholar
• Aktaş Karabay E, Aksu Çerman A, Demir D, et al. The effects of systemic psoriasis therapies on the C-Reactive protein and theNeutrophil-Lymphocyte ratio. Ann Dermatol. 2019;31(6):601–610. doi: 10.5021/ad.2019.31.6.601.
   PubMed Web of Science ®Google Scholar
• Kim DS, Shin D, Lee MS, et al. Assessments of neutrophil to lymphocyte ratio and platelet to lymphocyte ratio in korean patients with psoriasis vulgaris and psoriatic arthritis. J Dermatol. 2016;43(3):305–310. doi: 10.1111/1346-8138.13061.
   PubMed Web of Science ®Google Scholar
• Ergun T. Etiopathogenesis of psoriasis. TURKDERM - TurkArch Dermatol Venereol. 2008;42:18–22.
   Web of Science ®Google Scholar
• Mak RKH, Hundhausen C, Nestle FO. Progress in understanding the immunopathogenesis of psoriasis. Actas Dermosifiliogr. 2009;100(Suppl 2):2–13. doi: 10.1016/s0001-7310(09)73372-1.
   PubMedGoogle Scholar
• MacDonald A, Burden AD. Psoriasis: advances in pathophysiology and management. Postgrad Med J. 2007;83(985):690–697. doi: 10.1136/pgmj.2007.061473.
   PubMed Web of Science ®Google Scholar
• Villanova F, Di Meglio P, Nestle FO. Biomarkers in psoriasis and psoriatic arthritis. Ann Rheum Dis. 2013;72 Suppl 2:104–110. doi: 10.1136/annrheumdis-2012-203037.
   Google Scholar
• Yamanaka K, Umezawa Y, Yamagiwa A, et al. Biologic therapy improves psoriasis by decreasing thea ctivity of monocytes and neutrophils. J Dermatol. 2014;41(8):679–685. doi: 10.1111/1346-8138.12560.
   PubMed Web of Science ®Google Scholar
• An I, Ucmak D, Ozturk M. The effect of biological agent treatment on neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio, meanplatelet volume, and C-reactive protein in psoriasis patients. Postepy Dermatol Alergol. 2020;37(2):202–206. doi: 10.5114/ada.2020.94838.
   PubMed Web of Science ®Google Scholar
• Demirkol S, Balta S, Kucuk U, et al. Theneutrophil lymphocyte ratio may be useful inflammatory indicator before applying other expensive and invasive procedures. Indian J Nephrol. 2014;24(1):65–66. doi: 10.4103/0971-4065.125135.
   PubMedGoogle Scholar
• Zareifar S, Farahmand Far MR, Golfeshan F, et al. Changes in platelet count and mean platelet volume during infectious and inflammatory disease and their correlation with ESR and CRP. J Clin Lab Anal. 2014;28(3):245–248. doi: 10.1002/jcla.21673.
   PubMed Web of Science ®Google Scholar
• Chittawar S, Dutta D, Qureshi Z, et al. Neutrophil-lymphocyte ratio is a novel reliable predictor of nephropathy, retinopathy, and coronary artery disease in indians with type-2 diabetes. Indian J Endocrinol Metab. 2017;21(6):864–870. doi: 10.4103/ijem.IJEM_197_17.
   PubMedGoogle Scholar
• Paliogiannis P, Satta R, Deligia G, et al. Associations between the neutrophil-to-lymphocyte and theplatelet-to-lymphocyte ratios and the presence and severity of psoriasis: a systematic review and meta-analysis. Clin Exp Med. 2019;19(1):37–45. doi: 10.1007/s10238-018-0538-x.
   PubMed Web of Science ®Google Scholar
• Ataseven A, Temiz SA, Eren G, et al. Comparison of anti-TNF and IL-inhibitors treatments in patients with psoriasis in terms of response to routine laboratory parameter dynamics. J Dermatolog Treat. 2022;33(2):1091–1096. doi: 10.1080/09546634.2020.1801975.
   PubMed Web of Science ®Google Scholar
• Asahina A, Kubo N, Umezawa Y, et al. Neutrophil-lymphocyte ratio, platelet-lymphocyte ratio and mean platelet volume in japanese patients with psoriasis and psoriatic arthritis: Response to therapy with biologics. J Dermatol. 2017;44(10):1112–1121. doi: 10.1111/1346-8138.13875.
   PubMed Web of Science ®Google Scholar
• Najar Nobari N, Shahidi Dadras M, Nasiri S, et al. Neutrophil/platelet to lymphocyte ratio in monitoring of response to TNF-α inhibitors in psoriatic patients. DermatolTher. 2020;33(4):e13457.
   Google Scholar
• An İ, Aksoy M, Ayhan E, et al. The effect of secukinumab treatment on inflammatory parameters in patients with psoriasis: a multicentre restrospective study. Int J ClinPract. 2021;75(6):e14114.
   PubMed Web of Science ®Google Scholar
• Kaplan ZS, Jackson SP. The role of platelets in atherothrombosis. Hematology Am Soc Hematol Educ Program. 2011;2011(1):51–61. doi: 10.1182/asheducation-2011.1.51.
   PubMedGoogle Scholar
• Yi P, Jiang J, Wang Z, et al. Comparison of mean platelet volume (MPV) and red blood cell distribution width (RDW) between psoriasis patients and controls: a systematic review and meta-analysis. Plos One. 2022;17(2):e0264504. doi: 10.1371/journal.pone.0264504.
   PubMed Web of Science ®Google Scholar
• Liu P, Kuang Y, Ye L, et al. Predicting the risk of psoriatic arthritis in plaque psoriasis patients: Development and assessment of a new predictive nomogram. Front Immunol. 2021;12:740968. doi: 10.3389/fimmu.2021.740968.
   PubMed Web of Science ®Google Scholar
• Strober B, Teller C, Yamauchi P, et al. Effects of etanercept on C-reactive protein levels in psoriasis and psoriatic arthritis. Br J Dermatol. 2008;159(2):322–330. doi: 10.1111/j.1365-2133.2008.08628.x.
   PubMed Web of Science ®Google Scholar
• Coimbra S, Oliveira H, Reis F, et al. C-reactive protein and leucocyte activation in psoriasis vulgaris according to severity and therapy. J Eur Acad Dermatol Venereol. 2010;24(7):789–796. doi: 10.1111/j.1468-3083.2009.03527.x.
   PubMed Web of Science ®Google Scholar
• Chodorowska G, Wojnowska D, Juszkiewicz-Borowiec M. C-reactive protein and alpha2-macroglobulin plasma activity in medium-severe and severe psoriasis. J Eur Acad Dermatol Venereol. 2004;18(2):180–183. doi: 10.1111/j.1468-3083.2004.00863.x.
   PubMed Web of Science ®Google Scholar
• Montaudié H, Albert-Sabonnadière C, Acquacalda E, et al. Impact of systemic treatment of psoriasis on inflammatory parameters and markers of comorbidities and cardiovascular risk: results of a prospective longitudinal observational study. J Eur Acad Dermatol Venereol. 2014;28(9):1186–1191. doi: 10.1111/jdv.12255.
   PubMed Web of Science ®Google Scholar